Lacosamide

Drug Profile

Lacosamide

Alternative Names: ADD 234037; Erlosamide; Harkoseride; SPM 927; SPM 929; Vimpat; VIMPATÒ

Latest Information Update: 21 Jun 2017

Price : $50

At a glance

  • Originator University of Houston
  • Developer Daiichi Sankyo Company; UCB
  • Class Acetamides; Analgesics; Antiepileptic drugs; Neuroprotectants; Small molecules
  • Mechanism of Action CRMP2 protein modulators; Glycine NMDA-associated antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Partial epilepsies
  • Phase III Generalised seizures; Tonic-clonic epilepsy
  • Preclinical Pain
  • No development reported Essential tremor; Fibromyalgia; Osteoarthritis; Sleep disorders
  • Discontinued Migraine; Neuropathic pain

Most Recent Events

  • 22 Apr 2017 Subgroup analyses of efficacy and adverse event data from a phase III trial in Partial seizures presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 28 Mar 2017 UCB Pharma completes a phase I trial in Healthy volunteers in China (NCT03086382)
  • 22 Mar 2017 The US Patent and Trademark Office confirms validity of US patent RE 38 551 filed against UCB by Argentum Pharmaceuticals for obviousness
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top